Although novel c-MET (capmatinib, tepotinib) and EGFR inhibitors (osimertinib, lazertinib) have received limited approval for the treatment of various cancers, their high cost limits patient accessibility, particularly in the developing world. This evidence concerns the gene MET and cancer.